🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

PURPOSE 2 RCT🔥 Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons The HIV incidence with twice-yearly lenacapavir was significantly lower than the background incidence and the incidence with F/TDF #idxposts nejm.org/doi/full/10.10…

PURPOSE 2: In a phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background incidence and the incidence with emtricitabine–tenofovir disoproxil fumarate. Full trial results: nej.md/4fFWVzJ

Twice-yearly Lenacapavir injections reduce #HIVInfection risk by 96%, outperforming daily oral PrEP in adherence and effectivity, Emory University-led trial reports in NEJM. Emory University @nejm doi.org/g8r8qf medicalxpress.com/news/2024-11-c…

Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the results of ⁦Gilead Sciences⁩ PURPOSE-2 Study. nejm.org/doi/full/10.10…

Twice-Yearly #Lenacapavir for #HIV Prevention was superior to daily oral emtricitabine–tenofovir disoproxil fumarate (F/TDF) in reducing HIV infection (incidence rate ratio, 0.11; 95% CI, 0.02 to 0.51; P=0.002) & background incidence (incidence rate ratio 0.04)

Twice-Yearly Lenacapavir for PrEP Reduces HIV Infections by 96% nanoappsmedical.com/twice-yearly-l… cc. Amanda Scott Heinz V. Hoenen 🌻 Frank Boehm🌻

En este estudio fase 3 que incluyó a 3265 personas hombres y de género diverso, la incidencia de VIH con LENACAPAVIR (administrado dos veces al año) fue significativamente menor que la incidencia de fondo y la incidencia con F/TDF. N Engl J Med 2024; DOI: 10.1056/NEJMoa2411858

Game-changer for HIV prevention! The twice-yearly injection of lenacapavir showed a 96% reduction in HIV infections in the PURPOSE 2 trial. Source: Emory University News Center, Nov. 27, 2024

#Lenacapavir “This is a considerable and profound advancement in medicine, especially for people whose circumstances don’t allow them to take a daily oral medication, and for those among populations disproportionately impacted by #HIV.”  Colleen Kelley news.emory.edu/stories/2024/1…

Today, on World AIDS Day, Unitaid highlights lenacapavir—a powerful tool to help end HIV as a public health threat. We are actively working to ensure it reaches those most at risk, as quickly as possible. Together, we can make this a reality. Learn more: unitaid.org/news-blog/unit…

Lessons from dolutegravir show what’s possible: strategic partnerships and market interventions can make revolutionary medicines affordable and accessible. Unitaid is applying this model to unlock lenacapavir’s potential. Find out more: unitaid.org/news-blog/from…

HAPPENING NOW! AVAC's executive director Mitchell Warren kicks off today's webinar where we'll dive into the latest updates in the PURPOSE trials and what's next for #lenacapavir, the twice-yearly injectable #PrEP. Follow this 🧵 for live updates from the meeting.

Gilead’s Moupali Das, MD, MPH recognizes the importance of community engagement: “Thank you to AVAC for all the work that you’ve done to work with advocates to help educate and train people to engage in clinical trials. We could not have done this program without the larger community.”

Science’s 2024 Breakthrough of the Year is lenacapavir, an injectable drug that demonstrated remarkable success at preventing HIV infection with one shot every 6 months. Learn more about this year's #BOTY and other big advances in science: scim.ag/3Bd6ibq

#GileadNews: Today at #CROI2025, we announced initial data about our investigational once-yearly medication for HIV prevention. This is part of our mission to continue to innovate new person-centered #HIV prevention options. Learn more: gilead.inc/3FlRjNP

Dr. Moupali Das, MD, MPH from Gilead Sciences presented their Phase 1 results on once-yearly intramuscular lenacapavir for #HIVprevention. Study showed that both formulations sustained high drug concentrations for over 56 weeks. #CROI2025 Conference of Opportunistic Infections contagionlive.com/view/gilead-s-…

This annual shot might protect against HIV infections trib.al/jDdxIF1

ICYMI: Dr. Moupali Das, MD, MPH presented data at #CROI2025 showing Gilead Sciences's once-yearly Lenacapavir formulations for HIV PrEP sustain efficacy for 56 weeks. The phase 1 study paves the way for improved adherence & HIV prevention Conference of Opportunistic Infections The Lancet contagionlive.com/view/gilead-s-…

#MedTwitter I’ve joined Bluesky. Moupali Das, MD, MPH.bsky.social Let’s connect there!

#GileadNews: The FDA has approved our injectable HIV-1 prevention medication, making it the first and only twice-yearly #HIV prevention option in the U.S. This approval is helping to usher in the future of prevention as we work to help end the epidemic. gilead.inc/4e9KI6B